681 results on '"Sutter, Gerd"'
Search Results
202. Development and Immunologic Characterization of Multi-Antigen Expressing Attenuated Poxviruses for Immunotherapy of CMV Infection in HSCT Recipients.
203. A Toll-like receptor–independent antiviral response induced by double-stranded B-form DNA
204. 400: Vaccination of Dendritic Cells with PSA Encoding Modified Vaccinia Virus Ankara (MVA-PSA) Elicits PSA-Specific T-Cells in Vitro
205. Protection of Rhesus Monkeys against Infection with Minimally Pathogenic Simian-Human Immunodeficiency Virus: Correlations with Neutralizing Antibodies and Cytotoxic T Cells
206. Role of Viral Factor E3L in Modified Vaccinia Virus Ankara Infection of Human HeLa Cells: Regulation of the Virus Life Cycle and Identification of Differentially Expressed Host Genes
207. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)
208. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
209. Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens
210. Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia Virus
211. Melanoma-Reactive Class I-Restricted Cytotoxic T Cell Clones Are Stimulated by Dendritic Cells Loaded with Synthetic Peptides, but Fail to Respond to Dendritic Cells Pulsed with Melanoma-Derived Heat Shock Proteins In Vitro
212. HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway
213. Multispecific Vaccine-Induced Mucosal Cytotoxic TLymphocytes Reduce Acute-Phase Viral Replication but Fail inLong-Term Control of Simian Immunodeficiency VirusSIVmac239
214. A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens
215. Partial tyrosinase‐specific self tolerance by HLA‐A*0201‐restricted cytotoxic T lymphocytes in mice and man
216. Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells TransducedEx Vivowith a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial
217. Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen Delivery
218. Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3L
219. Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release
220. Human Papillomavirus Type 16 L1 Capsomeres Induce L1-Specific Cytotoxic T Lymphocytes and Tumor Regression in C57BL/6 Mice
221. Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
222. IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice
223. 12: Local IFN-I responses orchestrate cytokine responses and confer protection upon vaccinia virus infection
224. Recombinant poxvirus vaccines in biomedical research.
225. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines
226. Differences Between T Cell Epitopes Recognized After Immunization and After Infection
227. Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a rapid transient selection strategy
228. Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08
229. Immunization of Rhesus Macaques with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen Induces Broad Simian Immunodeficiency Virus (SIV)-Specific T-Cell Responses and Reduces Initial Viral Replication but Does Not Prevent Disease Progression following Challenge with Pathogenic SIVmac239
230. Tat-Vaccinated Macaques Do Not Control Simian Immunodeficiency Virus SIVmac239 Replication
231. Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques
232. Myxoma Virus Leukemia-Associated Protein Is Responsible for Major Histocompatibility Complex Class I and Fas-CD95 Down-Regulation and Defines Scrapins, a New Group of Surface Cellular Receptor Abductor Proteins
233. Construction and Isolation of Recombinant MVA.
234. Live Viral Vectors.
235. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity
236. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model
237. Recombinant Vaccinia Virus MVA for Generation and Analysis of T Cell Responses Against Tumor Associated Antigens.
238. Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope
239. Stable expression of HIV-1 Nef induces changes in growth properties and activation state of human astrocytes
240. Feline Calicivirus Capsid Protein Expression and Capsid Assembly in Cultured Feline Cells
241. Rescue of measles virus using a replication-deficient vaccinia-T7 vector
242. 117 : Toll-like receptor and RIG-I like helicase crosstalk is essential to protect against lethal infection with vesicular stomatitis virus
243. Non‐replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase
244. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus
245. Preclinical evaluation of influenza vaccines based on replication-deficient poxvirus vector MVA.
246. Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells.
247. Induction of Noxa-Mediated Apoptosis by Modified Vaccinia Virus Ankara Depends on Viral Recognition by Cytosolic Helicases, Leading to IRF-3/IFN-β-Dependent Induction of Pro-Apoptotic Noxa.
248. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
249. Postexposure Immunization with Modified Vaccinia Virus Ankara or Conventional Lister Vaccine Provides Solid Protection in a Murine Model of Human Smallpox.
250. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.